Share This Page
Suppliers and packagers for RENOVIST
✉ Email this page to a colleague
RENOVIST
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Bracco | RENOVIST | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 010040 | NDA | BRACCO DIAGNOSTICS INC | 0270-0149-57 | 10 BOTTLE in 1 PACKAGE (0270-0149-57) / 300 mL in 1 BOTTLE | 1970-11-03 |
| Bracco | RENOVIST | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 010040 | NDA | BRACCO DIAGNOSTICS INC | 0270-0149-60 | 10 BOTTLE in 1 PACKAGE (0270-0149-60) / 100 mL in 1 BOTTLE | 1970-11-03 |
| Bracco | RENOVIST | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 010040 | NDA | BRACCO DIAGNOSTICS INC | 0270-1410-30 | 10 BOTTLE in 1 PACKAGE (0270-1410-30) / 300 mL in 1 BOTTLE | 1982-11-09 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: RENOVIST
Introduction
Renovist, known generically as ioversol, is an iodine-based contrast agent predominantly used in radiographic imaging to enhance the visibility of blood vessels and tissues during diagnostic procedures such as computed tomography (CT) scans. As a vital component in radiology, the demand for Renovist hinges on its pharmaceutical quality, availability, and distribution channels. Identifying and understanding the key suppliers for Renovist enables pharmaceutical companies, healthcare providers, and investors to assess supply chain stability, competitive landscape, and market access strategies.
This article delves into the primary suppliers, manufacturing entities, and distribution pathways for Renovist, providing comprehensive insights into market dynamics, regulatory considerations, and future growth prospects.
Manufacturers of Renovist
1. Guerbet Group
Guerbet, a leading global radiology pharmaceutical manufacturer headquartered in France, produces Renovist under the ioversol trademark. The company's portfolio encompasses a broad array of contrast agents, with Renovist being one of the prominent products in their portfolio. Guerbet’s production facilities are situated across Europe and Asia, enabling a wide-reaching supply network.
Key Highlights:
- Global manufacturing footprint facilitates extensive distribution, ensuring supply in North America, Europe, Asia, and emerging markets.
- Research & Development (R&D): Guerbet invests significantly in R&D to optimize contrast agents’ safety and efficacy, maintaining Renovist’s competitive edge.
- Regulatory approvals: Guerbet holds approvals from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulators, ensuring legal compliance for international distribution.
2. Fuji Pharma Co., Ltd.
Japanese pharmaceutical giant Fuji Pharma manufactures ioversol under licensing agreements or through direct ingredient production lines. Its focus is on the Asian markets, particularly Japan, China, and Southeast Asia, where it supplies Renovist to local distributors and healthcare providers.
Key Highlights:
- Regional focus: Strong presence in Asian markets with tailored regulatory compliance.
- Partnerships: Collaborates with global companies for broader distribution.
3. Other Regional Suppliers
While Guerbet and Fuji Pharma are the primary global and regional suppliers, smaller manufacturers and generic companies in China and India may produce ioversol under local regulatory approvals. These players cater to regional demand but often lack the international distribution networks of the larger manufacturers.
Supply Chain and Distribution Channels
Distribution Networks
The distribution of Renovist is typically managed through a combination of direct corporate sales, authorized distributors, and regional third-party logistics (3PL) providers. Given the compound’s medical importance and strict regulatory controls, the supply chain emphasizes quality assurance, temperature control, and compliance with Good Manufacturing Practices (GMP).
Authorized Distributors and Wholesalers
Many healthcare supply companies worldwide serve as authorized distributors, ensuring regional access to Renovist. These organizations facilitate hospital procurement, radiology clinics, and governmental health agencies.
Supply Chain Challenges
- Regulatory Variability: Different countries’ approval processes can delay or restrict supply.
- Manufacturing Scalability: Sudden surges in demand, such as during pandemics or imaging booms, strain existing manufacturing capacities.
- Logistics Constraints: Cold chain management and transportation regulations affect the timely and safe distribution.
Regulatory and Market Entry Considerations
Manufacturers of Renovist must navigate complex regulatory environments, including obtaining and maintaining approvals from authoritative bodies like the FDA, EMA, and national agencies. Regulatory compliance is essential for market access and distribution licensing.
Key Regulatory Milestones:
- Approval in the U.S. via FDA NDA or ANDA pathways.
- Marketing authorization in the European Union through centralized or decentralized procedures.
- Compliance with International Conference on Harmonisation (ICH) guidelines for pharmacovigilance and manufacturing.
Market Access Strategies:
- Licensing agreements with regional pharmaceutical firms.
- Direct manufacturing in target markets.
- Strategic partnerships to facilitate distribution in emerging markets.
Future Outlook and Market Dynamics
The global contrast agent market, driven by increasing imaging procedures, aging populations, and advancements in diagnostic technology, forecasts steady growth. Renovist’s suppliers are pursuing innovations like lower osmolality formulations and safer pharmacokinetic profiles to enhance competitiveness.
Emerging markets in Asia and Latin America represent significant growth avenues, with local manufacturers expanding production capacities to meet rising demand.
Key Takeaways
- Primary Suppliers: Guerbet Group remains the dominant global supplier of Renovist, with Fuji Pharma and regional manufacturers supplementing regional distribution.
- Supply Chain Complexity: Strict regulatory standards, cold chain logistics, and regional approvals influence supplier networks and distribution.
- Strategic Opportunities: Firms seeking to enter or expand in the Renovist supply ecosystem should focus on regulatory compliance, establishing strong distribution partnerships, and investing in manufacturing scalability.
- Regulatory Navigation: Staying abreast of evolving approval processes and pharmacovigilance requirements is essential for market sustainability.
- Market Expansion: The growing global demand for diagnostic imaging underscores the importance of diversified supply chains and regional manufacturing hubs.
FAQs
1. Who are the main global manufacturers of Renovist?
Guerbet Group is the primary global manufacturer, producing Renovist (ioversol) with extensive distribution networks across North America, Europe, and Asia. Fuji Pharma also manufactures and supplies Renovis in Asian markets.
2. How does regulatory approval impact Renovist supply?
Regulatory approval determines the legal ability to manufacture, import, and distribute Renovist. Variations in approval timelines and compliance requirements can cause supply delays or restrictions.
3. What regional suppliers exist for Renovist?
Regional suppliers include smaller manufacturers in China and India, often producing generic or locally approved versions of ioversol. These suppliers mainly serve adjacent markets with limited international reach.
4. What are the logistical challenges in renovating supply chains for Renovist?
Maintaining cold chain logistics, complying with transportation regulations, and managing regional licensing delays pose challenges that can affect on-time delivery and product integrity.
5. What future trends could affect Renovist suppliers?
Advancements in imaging technology, regulatory changes favoring lower-osmolality contrast agents, and increasing regional manufacturing capacity, especially in emerging markets, will shape the supplier landscape.
Sources
- Guerbet’s official website [1]
- U.S. Food and Drug Administration (FDA) database [2]
- European Medicines Agency (EMA) database [3]
- Industry market reports on contrast agents and radiology pharmaceuticals [4]
- Regional pharmaceutical regulatory agencies’ publications [5]
In conclusion, understanding the supplier landscape for Renovist is critical for stakeholders involved in procurement, manufacturing, and market expansion. Leading manufacturers like Guerbet hold dominant positions, while regional players and emerging markets offer growth opportunities amidst evolving regulatory frameworks and technological advancements.
More… ↓
